dc.contributor.author | Mirelis, Jesús G | |
dc.contributor.author | Escobar-Lopez, Luis | |
dc.contributor.author | Ochoa, Juan Pablo | |
dc.contributor.author | Espinosa, María Ángeles | |
dc.contributor.author | Villacorta, Eduardo | |
dc.contributor.author | Navarro, Marina | |
dc.contributor.author | Casas, Guillem | |
dc.contributor.author | Mora-Ayestarán, Nerea | |
dc.contributor.author | Barriales-Villa, Roberto | |
dc.contributor.author | Mogollón-Jiménez, María Victoria | |
dc.contributor.author | García-Pinilla, José M | |
dc.contributor.author | García-Granja, Pablo E | |
dc.contributor.author | Climent, Vicente | |
dc.contributor.author | Palomino-Doza, Julian | |
dc.contributor.author | García-Álvarez, Ana | |
dc.contributor.author | Álvarez-Barredo, María | |
dc.contributor.author | Cabrera-Borrego, Eva | |
dc.contributor.author | Ripoll-Vera, Tomás | |
dc.contributor.author | Peña-Peña, María Luisa | |
dc.contributor.author | Rodríguez-González, Elena | |
dc.contributor.author | Gallego-Delgado, María | |
dc.contributor.author | Gonzalez-Carrillo, Josefa | |
dc.contributor.author | Fernández-Ávila, Ana | |
dc.contributor.author | Rodríguez-Palomares, José F | |
dc.contributor.author | Brugada, Ramón | |
dc.contributor.author | Bayes-Genis, Antoni | |
dc.contributor.author | Dominguez, Fernando | |
dc.contributor.author | García-Pavía, Pablo | |
dc.date.accessioned | 2023-03-16T11:04:20Z | |
dc.date.available | 2023-03-16T11:04:20Z | |
dc.date.issued | 2022-07 | |
dc.identifier.citation | Eur J Heart Fail. 2022 Jul;24(7):1183-1196 | es_ES |
dc.identifier.other | http://hdl.handle.net/10668/21940 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/15643 | |
dc.description.abstract | Genotype and left ventricular scar on cardiac magnetic resonance (CMR) are increasingly recognized as risk markers for adverse outcomes in non-ischaemic dilated cardiomyopathy (DCM). We investigated the combined influence of genotype and late gadolinium enhancement (LGE) in assessing prognosis in a large cohort of patients with DCM.
Outcomes of 600 patients with DCM (53.3 ± 14.1 years, 66% male) who underwent clinical CMR and genetic testing were retrospectively analysed. The primary endpoints were end-stage heart failure (ESHF) and malignant ventricular arrhythmias (MVA). During a median follow-up of 2.7 years (interquartile range 1.3-4.9), 24 (4.00%) and 48 (8.00%) patients had ESHF and MVA, respectively. In total, 242 (40.3%) patients had pathogenic/likely pathogenic variants (positive genotype) and 151 (25.2%) had LGE. In survival analysis, positive LGE was associated with MVA and ESHF (both, p < 0.001) while positive genotype was associated with ESHF (p = 0.034) but not with MVA (p = 0.102). Classification of patients according to genotype (G+/G-) and LGE presence (L+/L-) revealed progressively increasing events across L-/G-, L-/G+, L+/G- and L+/G+ groups and resulted in optimized MVA and ESHF prediction (p < 0.001 and p = 0.001, respectively). Hazard ratios for MVA and ESHF in patients with either L+ or G+ compared with those with L-/G- were 4.71 (95% confidence interval: 2.11-10.50, p < 0.001) and 7.92 (95% confidence interval: 1.86-33.78, p < 0.001), respectively.
Classification of patients with DCM according to genotype and LGE improves MVA and ESHF prediction. Scar assessment with CMR and genotyping should be considered to select patients for primary prevention implantable cardioverter-defibrillator placement. | es_ES |
dc.description.sponsorship | This work was supported by grants from the Instituto de SaludCarlos III (ISCIII) (PI18/0004, PI19/01283, PI20/0320). (Co-fundedby European Regional Development Fund/European Social Fund‘A way to make Europe’/‘Investing in your future’). The HospitalUniversitario Puerta de Hierro Majadahonda, the Hospital Clinic,the Hospital Vall d’Hebron, the Hospital General UniversitarioGregorio Marañón and the Hospital Universitario Virgen de laArrixaca are members of the European Reference Network forrare, low-prevalence, and complex diseases of the heart (ERNGUARD-Heart). The CNIC is supported by the ISCIII, MCIN,the Pro-CNIC Foundation, and the Severo Ochoa Centers ofExcellence program (CEX2020-001041-S).Conflict of interest: none declared. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject.mesh | Cardiomyopathy, Dilated | es_ES |
dc.subject.mesh | Heart Failure | es_ES |
dc.subject.mesh | Arrhythmias, Cardiac | es_ES |
dc.subject.mesh | Cicatrix | es_ES |
dc.subject.mesh | Contrast Media | es_ES |
dc.subject.mesh | Female | es_ES |
dc.subject.mesh | Gadolinium | es_ES |
dc.subject.mesh | Genotype | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | Magnetic Resonance Imaging, Cine | es_ES |
dc.subject.mesh | Male | es_ES |
dc.subject.mesh | Predictive Value of Tests | es_ES |
dc.subject.mesh | Prognosis | es_ES |
dc.subject.mesh | Retrospective Studies | es_ES |
dc.title | Combination of late gadolinium enhancement and genotype improves prediction of prognosis in non-ischaemic dilated cardiomyopathy. | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.identifier.pubmedID | 35485241 | es_ES |
dc.format.volume | 24 | es_ES |
dc.format.number | 7 | es_ES |
dc.format.page | 1183 | es_ES |
dc.identifier.doi | 10.1002/ejhf.2514 | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | es_ES |
dc.contributor.funder | Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) | es_ES |
dc.contributor.funder | Fundación ProCNIC | es_ES |
dc.contributor.funder | Ministerio de Ciencia e Innovación. Centro de Excelencia Severo Ochoa (España) | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1879-0844 | es_ES |
dc.relation.publisherversion | 10.1002/ejhf.2514 | es_ES |
dc.identifier.journal | European journal of heart failure | es_ES |
dc.repisalud.orgCNIC | CNIC::Grupos de investigación::Miocardiopatías Hereditarias | es_ES |
dc.repisalud.orgCNIC | CNIC::Grupos de investigación::Investigación traslacional en insuficiencia cardiaca e hipertensión pulmonar | es_ES |
dc.repisalud.institucion | CNIC | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PI18/0004 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PI19/01283 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PI20/0320 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/CEX2020-001041-S | es_ES |